Drug exposure may have a substantial influence on COVID-19 prognosis among residents of long-term care facilities: an exploratory analysis

Abstract

Objectives To explore the association between drug exposure and SARS-CoV-2 prognosis among elderly living in long-term care facilities (LTC) Design We carried out a cross-sectional study among old people living in LTC which had a proven SARS-CoV-2 infection, including socio-demographic data, comorbidities and drug intake at the moment of the diagnosis. The study was focused on ACE2 inhibitors, ARA-II blockers, inhaled bronchodilators, oral corticoids, platelet antiaggregants, oral anti-coagulants, statins and Vitamin D. Results 1 306 individuals were included, with a mean age of 86.7 years and 72.3% were females. The case fatality rate was of 24.4%. Among the studied exposures platelet antiaggregant were the most prevalent (24.7%). After adjusting for propensity score, the intake of inhaled corticoids (OR 0.73; p=0.03), statins (OR 0.65; p=0.03) were found to be protective factors of death, whereas ACE2 inhibitor showed an almost significant association (OR 0.73, p=0.07). Conclusions Considering the high prevalence of drug intake among elderly, drug exposure may be an important Covid-19 disease modifier in LTC residents and should be considered when exploring prognostic risk factors associated to Covid-19.

The interplay between infection risk factors of SARS-CoV-2 and mortality: a cross-sectional study from a cohort of long-term care nursing home residents

“…We hypothesized that in the context of extremely high attack rates in LTCF, once SARS-CoV-2 infection occurs tends to behave independently of underlying risk factors, like a primary pathogen. Furthermore, existing medications may have had a substantial effect against infection or severe disease in a population that is usually polymedicated [ 35 ].…”